期刊
DIABETES
卷 61, 期 2, 页码 321-328出版社
AMER DIABETES ASSOC
DOI: 10.2337/db11-1050
关键词
-
资金
- Juvenile Diabetes Research Foundation [1-2003-78, 1-2006-29]
- Diabetes UK [RD05/003059]
- National Institute of Diabetes and Digestive and Kidney Diseases [DK065171]
- Wellcome Trust [WT081713]
- American Diabetes Association
- Medical Research Council Centre
- Diabetes Research and Wellness Foundation
- Gates Cambridge Trust
- MRC
- Medical Research Council [G0600717B] Funding Source: researchfish
As patients decline from health to type 2 diabetes, glucose-stimulated insulin secretion (GSIS) typically becomes impaired. Although GSIS is driven predominantly by direct sensing of a rise in blood glucose by pancreatic beta-cells, there is growing evidence that hypothalamic neurons control other aspects of peripheral glucose metabolism. Here we investigated the role of the brain in the modulation of GSIS. To examine the effects of increasing or decreasing hypothalamic glucose sensing on glucose tolerance and insulin secretion, glucose or inhibitors of glucolcinase, respectively, were infused into the third ventricle during intravenous glucose tolerance tests (IVGTTs). Glucose-infused rats displayed improved glucose handling, particularly within the first few minutes of the IVGTT, with a significantly lower area under the excursion curve within the first 10 min (AUC(0-10))). This was explained by increased insulin secretion. In contrast, infusion of the glucokinase inhibitors glucosarnine or mannoheptulose worsened glucose tolerance and decreased GSIS in the first few minutes of IVGTT. Our data suggest a role for brain glucose sensors in the regulation of GSIS, particularly during the early phase. We propose that pharmacological agents targeting hypothalamic glucose-sensing pathways may represent novel therapeutic strategies for enhancing early phase insulin secretion in type 2 diabetes. Diabetes 61:321-328, 2012
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据